Keros Therapeutics (KROS)
(Real Time Quote from BATS)
$54.74 USD
-1.06 (-1.90%)
Updated Sep 23, 2024 01:40 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
KROS 54.74 -1.06(-1.90%)
Will KROS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for KROS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KROS
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
KROS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for KROS
Opaleye Management Inc. Increases Stake in Codexis Inc.
Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc.
Opaleye Management Inc. Reduces Stake in Protara Therapeutics Inc.
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
Keros Therapeutics price target lowered by $5 at BofA, here's why